Analyse av kutant fosforylert alfa-synuklein for å identifisere pasienter med risiko for å utvikle seg fra essensiell tremor til Parkinsons sykdom (Syn-T)
Analyse av kutan fosforylert alfa-synuklein for å identifisere pasienter med risiko for å utvikle seg fra essensiell tremor til Parkinsons sykdom
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.
Primary Objectives
- Identify which ET patients have P-SYN pathology indicative of prodromal PD
- Predict which patients are most likely to phenoconvert to PD
Studieoversikt
Status
Status
Forhold
Forhold
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Jeannie Director of Clinical Research
- Telefonnummer: 371 480-434-6446
- E-post: ClinicalResearch@cndlifesciences.com
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85258
- Rekruttering
- Movement Disorders Center of Arizona
-
Ta kontakt med:
- Danica Evidente
- Telefonnummer: 480-526-5441
- E-post: danica@movementdisorders.us
-
Hovedetterforsker:
- Virgilio Gerald H Evidente, MD
-
Scottsdale, Arizona, Forente stater, 85258
- Rekruttering
- CND Clinical Research Center
-
Ta kontakt med:
- Jeannie Director of Clinical Research
- Telefonnummer: 371 480-434-6446
- E-post: ClinicalResearch@cndlifesciences.com
-
Hovedetterforsker:
- Padma Mahant, MD
-
-
California
-
Irvine, California, Forente stater, 92617
- Har ikke rekruttert ennå
- University of California Irvine Health
-
Ta kontakt med:
- Shivani Venkateswaran
- E-post: shivanv1@uci.edu
-
Hovedetterforsker:
- Ann Ly, MD
-
Underetterforsker:
- Niki Maki, MD
-
Los Angeles, California, Forente stater, 90048
- Har ikke rekruttert ennå
- Cedars-Sinai Medical Center
-
Hovedetterforsker:
- Michele Tagliati, MD
-
Ta kontakt med:
- Anne Tran
- Telefonnummer: 310-423-1697
- E-post: anne.tran@cshs.org
-
Ta kontakt med:
- Michele Lima Gregorio, PhD
- Telefonnummer: 424-315-0021
- E-post: michele.gregorio@cshs.org
-
-
Florida
-
Orlando, Florida, Forente stater, 32825
- Rekruttering
- Neurology One
-
Hovedetterforsker:
- Ramon L Rodriguez, MD, FAAN
-
Ta kontakt med:
- Jinna Santiago, RN, CRC
- Telefonnummer: 110 407-706-3060
- E-post: jsantiago@n1research.org
-
Ta kontakt med:
- Victor Lameda, CRC
- Telefonnummer: 109 407-706-3060
- E-post: vlameda@n1research.org
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- University of Kansas Medical Center
-
Underetterforsker:
- Kelly Lyons, PhD
-
Ta kontakt med:
- Kim Lee, Clinical Research Coordinator
- Telefonnummer: 913-588-0013
- E-post: klee9@kumc.edu
-
Hovedetterforsker:
- Angela Richmond, MD
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- Norton Healthcare
-
Ta kontakt med:
- Andrea J Gambrell, RN, BSN, CCM
- Telefonnummer: 502-446-8544
- E-post: andrea.gambrell@nortonhealthcare.org
-
Ta kontakt med:
- Hannah Scully, RN
- Telefonnummer: 502-588-0719
- E-post: hannah.scully@nortonhealthcare.org
-
Hovedetterforsker:
- Jason Crowell, MD
-
Underetterforsker:
- Justin Phillips, MD
-
-
Michigan
-
Farmington Hills, Michigan, Forente stater, 48334
- Rekruttering
- Quest Research Institute
-
Ta kontakt med:
- Denise Morgott
- Telefonnummer: 248-957-8940
- E-post: denise.morgott@questri.com
-
Hovedetterforsker:
- Aaron Ellenbogen, DO
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38157
- Rekruttering
- Veracity Neurosciences LLC
-
Ta kontakt med:
- Hannah Touliatos
- Telefonnummer: 901-443-9170
- E-post: hannah@veracityneuroscience.com
-
Hovedetterforsker:
- Mark LeDoux, MD, PhD
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center
-
Ta kontakt med:
- Jackie Harris, RMA, CTRC IV
- Telefonnummer: 615-936-3833
- E-post: jacqueline.c.harris@vumc.org
-
Ta kontakt med:
- Keimora Wright, CTRC II
- Telefonnummer: 615-322-0530
- E-post: keimora.wright@vumc.org
-
Hovedetterforsker:
- Cherrie Yu, MD
-
Underetterforsker:
- Amanda Currie, MD
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Ta kontakt med:
- Haneyeh Primary Research Coordinator
- Telefonnummer: 713-798-5120
- E-post: haneyeh.amidi@bcm.edu
-
Ta kontakt med:
- Rory Research Manager
- Telefonnummer: 713-798-5989
- E-post: Rory.Mahabir@bcm.edu
-
Hovedetterforsker:
- Steven Bellows, MD
-
Underetterforsker:
- Karim Makhoul, MD
-
Underetterforsker:
- Yutong Taneff, NP
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Subjects will be enrolled from up to 18 sites across the US from academic institutions and private clinics.
Beskrivelse
Inclusion Criteria:
- Age 50-85 years old
- Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
- Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
- Willing to participate in all study procedures
- Able and willing to provide written informed consent
Exclusion Criteria:
- Under age 50, Over age 85
- Clinical evidence of severe peripheral vascular disease
- Clinically active coronary artery or cerebrovascular disease
- Participant is currently on anticoagulant or dual anti-platelet therapy
- Alcoholism
- Allergic reaction to local anesthesia
- History of or increased risk for impaired wound healing, scarring, or keloid formation
- Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
- History of other neurodegenerative disorder or evidence of neurological co-pathology
- Abnormal DaTscan
- Participant is currently receiving treatment with carbidopa-levodopa for PD
- Isolated focal tremors (head, voice)
- Task-specific tremor (e.g., primary writing tremor)
- Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
- Sudden onset and step-wise deterioration
- Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
|---|
|
Essential Tremor
Those diagnosed with Essential Tremor |
|
Essential Tremor Plus
Those diagnosed with Essential Tremor Plus |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quantity of P-SYN in skin
Tidsramme: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
Quantity of P-SYN in biopsies as a biomarker for disease progression |
From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
|
Rate of Phenoconversion
Tidsramme: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
Rate of phenoconversion from Essential Tremor to Parkinson's Disease over 24 months |
From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- CND-106
- R44NS143486-01 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .